305 studies found for:    Exclude Unknown | Expanded Access Studies
Show Display Options
Download search resultsDownload the search results for:
Exclude Unknown | Expanded Access Studies (305 records)
Download Content:
zip file readers with free trial periods: WinZip and PKZip
Rank Status Study
1 Available Early Patient Access Single Named Patient Program for the Use of Ulocuplumab for the Treatment of Multiple Myeloma
Conditions: Relapsed Multiple Myeloma;   Refractory Multiple Myeloma
Interventions: Drug: Ulocuplumab;   Drug: Lenalidomide;   Drug: Bortezomib;   Drug: Dexamethasone
2 Temporarily not available Safety and Tolerability of Cannabidiol in Subjects With Drug Resistant Epilepsy
Condition: Epilepsy
Intervention: Drug: Cannabidiol
3 Temporarily not available Compassionate Use of Deferiprone in Patients With PKAN
Condition: Pantothenate Kinase-Associated Neurodegeneration
Intervention: Drug: Deferiprone
4 Available Protocol for Continued Patient Access to Study Drug
Condition: Cancer
Intervention: Drug: LY2503029
5 Available Midostaurin Access Program for Newly Diagnosed FLT3 (ITD or TKD) Mutated AML Adult Patients Eligible for Standard Induction and Consolidation Chemotherapy.
Conditions: Acute Myeloid Leukemia (AML) With;   FLT3 Mutation, Internal Tandem Duplication (ITD) or Tyrosine Kinase Domain (TKD)
Intervention: Drug: Midostaurin
6 Temporarily not available Use of Well Known Drugs for New Destination - MS Improvement (MSNT)
Conditions: Multiple Sclerosis;   Autoimmune Diseases;   Disseminated or Multiple Sclerosis Nos;   Multiple Sclerosis, Acute Relapsing;   Multiple Sclerosis, Primary Progressive;   Multiple Sclerosis, Chronic Progressive
Intervention: Drug: Tetracycline - Statin - Antimycotic
7 Available Expanded Access Protocol to Provide Brincidofovir for the Treatment of Serious Adenovirus Infection or Disease
Condition: Adenovirus
Intervention: Drug: Brincidofovir
8 No longer available A Prospective, Multiparametric Biomarker Study to Identify Predictors of Treatment Response and Resistance in Patients With EGFR-mutated Non-small-cell Lung Cancer Receiving Maintenance Therapy With Either Afatinib or Pemetrexed With the AIO-TRK-0114 Study (MARBLE)
Condition: Non-small-cell Lung Cancer With Somatic EGFR Mutations
Intervention: Other: Collection of tumor and blood specimen
9 Available Deflazacort Expanded Access Program for Children, Adolescents and Adults With Duchenne Muscular Dystrophy
Condition: Duchenne Muscular Dystrophy
Intervention: Drug: Deflazacort
10 Available Compassionate Use Arm - ABI541 ABI for 10 NF2 Patients
Conditions: Neurofibromatosis Type 2;   Severe Profound Sensorineural Hearing Loss
Intervention: Device: Nucleus Profile ABI541 Auditory Brainstem Implant
11 Available An Expanded Access Study of Atezolizumab in Patients With Locally Advanced or Metastatic Urothelial Carcinoma After Failure With Platinum-Containing Chemotherapy
Condition: Urothelial Carcinoma
Intervention: Drug: Atezolizumab
12 Temporarily not available Autologous Platelet-rich Plasma (aPRP) for Complex Aortic Arch Surgerymacrovascular Operation
Condition: Autologous Blood Transfusion
Intervention: Procedure: Sorin XTRA/Sorin Group,
13 No longer available Compassionate Use of Aldoxorubicin in Sarcoma Patients Chemotherapy
Condition: Sarcoma
Intervention: Drug: aldoxorubicin
14 Available An Expanded Treatment Protocol of Panobinostat in Combination Therapy for Relapsed, and Relapsed and Refractory Multiple Myeloma
Condition: Multiple Myeloma
Intervention: Drug: Panobinostat
15 Available Domperidone Expanded Access Protocol for Patients With Gastrointestinal Disorders
Condition: Refractory Gastroesophageal Reflux Disease With Upper Gastrointestinal (GI) Symptoms, Gastroparesis, and Chronic Constipation
Intervention: Drug: Domperidone
16 Available Cannabidiol for Pediatric Epilepsy (Compassionate Use)
Condition: Refractory Childhood Epilepsy
Intervention: Drug: cannabidiol (CBD)
17 Available Rociletinib (CO-1686) USA Expanded Access Program
Condition: Non-small Cell Lung Cancer
Intervention: Drug: Rociletinib
18 No longer available Expanded Access Single Named Patient Program With Elotuzumab (BMS-901608) for the Treatment of Patient R-A With Relapsed/Refractory Multiple Myeloma
Condition: Multiple Myeloma
Intervention: Drug: Elotuzumab
19 Available Study of the Use of [18F]-DOPA in Hyperinsulinemic Hypoglycemia
Conditions: Hyperinsulinemic Hypoglycemia, Persistent;   Congenital Hyperinsulinism;   Persistent Hyperinsulinemic Hypoglycemia of Infancy (PHHI)
Intervention: Drug: 18 F-DOPA
20 Available EAP of CPX-351 for Patients 60-75 Years of Age With Secondary AML
Condition: Secondary AML
Intervention: Drug: CPX-351

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years